iOnctura and the EIC Accelerator: A New Angle on Pancreatic Cancer

30 September 2026987 words5 min

iOnctura, a clinical-stage oncology company based in Amsterdam and Geneva, develops cambritaxestat (IOA-289), an oral drug that blocks autotaxin, an enzyme that drives the fibrotic scar tissue around pancreatic tumours. Its EIC application said the funding would "accelerate the clinical development of IOA-289 as a treatment for pancreatic cancer through Phase I/II clinical trials, reach a major value inflection point and attract further financial investment", according to CORDIS.

The European Innovation Council granted €2,500,000 towards a €5.91 million project from October 2022 to March 2025. The final report says the first patient was dosed in Italy in November 2022 and 16 patients were treated across four dose levels in combination with chemotherapy, with dose escalation completed in February 2025 and doses of 100 to 800 mg twice daily judged safe and tolerable by a safety monitoring committee. ClinicalTrials.gov lists the trial as completed on 18 August 2025, with 16 participants and no results posted. The report also notes a caution: "some biomarkers suggest that the chemotherapy counteracts part of IOA-289 activity". In October 2025 iOnctura announced that the Phase Ib study had met its primary endpoint of safety, tolerability and anti-tumour responses, Syncona reported.

€2.50MEIC grant, 42% of a €5.91M project
16Patients in the Phase Ib
€80MSeries B with the EIC Fund, 2024
NonePancreatic Phase II found in sources checked, Nov 2026

Company file

Legal entity
iOnctura B.V., Amsterdam; operations also in Geneva
Drugs
Roginolisib (lead, PI3Kδ), cambritaxestat (IOA-289, autotaxin), IOA-359
Chief medical officer
Michael Lahn
Investors
Syncona, EIC Fund, M Ventures, Inkef, VI Partners, Schroders Capital, 3B Future Health Fund
Trial
AION-02, NCT05586516, Italy and UK
EIC project
CURE-PDAC, 1 Oct 2022 to 31 Mar 2025, closed
EIC funding
Blended finance

Where iOnctura Stands Now

The ESMO data showed no dose-limiting toxicities and consistent, durable falls in the tumour marker CA19-9 in higher-dose patients, which were associated with radiographic responses and survival, iOnctura said. The US Food and Drug Administration granted cambritaxestat orphan drug designation for pancreatic cancer in March 2024. iOnctura's €80 million Series B in June 2024 was aimed chiefly at its lead drug, roginolisib, for uveal melanoma and other cancers, according to its announcement. The report says a single-agent study of cambritaxestat in liver cancer was being planned. In July 2026 iOnctura's news page listed new proteomic data in metastatic pancreatic cancer and tumour profiling data in liver and bile duct cancers.

The record

Autotaxin inhibitor from first patient to ESMO data

The EIC project funded the first trial of cambritaxestat (IOA-289) in pancreatic cancer. iOnctura says the Phase Ib study met its primary endpoint; sources checked in November 2026 show no Phase II in pancreatic cancer, and iOnctura's lead asset is roginolisib.

  1. Oct 2022EIC project starts€5.91M project€2.50M grant
  2. Nov 2022First patient dosedPhase Ib, Italy
  3. Mar 2024FDA orphan drug designationPancreatic cancer
  4. Jun 2024Series BLed by Syncona, with the EIC Fund€80M
  5. Feb 2025Dose escalation complete16 patients, 100-800 mg twice daily
  6. Mar 2025EIC project endsLiver cancer study in planning
  7. Oct 2025ESMO dataCompany says primary endpoint met: safety, tolerability, responses

CORDIS, iOnctura, Syncona.

"These findings warrant continued scientific exploration in autotaxin inhibition."

Davide Melisi, lead investigator, University of Verona, October 2025

The Science: Breaking the Tumour's Shield

Pancreatic cancer has a five-year survival rate of 13%, the report says, and dense scar tissue blocks chemotherapy and immune cells. Autotaxin is key to driving that fibrosis, the report says. Cambritaxestat, taken as a capsule, is designed to reduce fibrosis, dampen tumour growth and help immune cells reach the tumour. It is the first autotaxin inhibitor tested in cancer patients, according to the company.

The trial

Patients per dose level in the Phase Ib study

Cambritaxestat was given orally twice daily with standard gemcitabine and nab-paclitaxel chemotherapy. No dose-limiting toxicities were reported.

Syncona / iOnctura, October 2025; NCT05586516.

What the EIC Project Promised, and What CORDIS Shows

The EIC project

EU contribution covers 42% of a €5.9M project

The CURE-PDAC project ran from October 2022 to March 2025. CORDIS lists it as closed. Other project costs are total cost minus EU contribution, not proof of company cash.

CORDIS project 190159801. Values in € millions.

The project promised Phase I/II development in pancreatic cancer and a value inflection point that would attract investment. The Phase Ib was completed and investment followed, including from the EIC Fund. Sources reviewed on 7 November 2026, including ClinicalTrials.gov and iOnctura's news page, do not show a Phase II in pancreatic cancer, and the report itself calls for larger studies and more work to find the best drug combinations. CORDIS lists the project as closed.

  1. Phase Ib completedDelivered16 patients, endpoint met per company.
  2. Orphan designationDeliveredFDA, March 2024.
  3. Follow-on investmentDelivered€80M Series B.
  4. Phase II in pancreatic cancerNot foundNone in sources checked, Nov 2026.

The Money

The Series B was led by Syncona, with the EIC Fund and existing investors. The EIC Fund's share, how much of the round goes to cambritaxestat versus roginolisib, and iOnctura's cash runway are not public.

The money

EIC grant and the Series B that followed

The Series B was led by Syncona with the EIC Fund, M Ventures, Inkef, VI Partners, Schroders Capital and 3B Future Health Fund. It was aimed mainly at lead asset roginolisib.

CORDIS; iOnctura, June 2024. Values in € millions.

What Cannot Be Checked

Questions for the EIC

Whether iOnctura will run a Phase II of cambritaxestat in pancreatic cancer, how much the EIC Fund invested, and whether the chemotherapy interaction flagged in the report has been resolved are not public.

Why Europe Should Care

Pancreatic cancer remains one of the deadliest cancers with few new treatment options. The EIC funded a European first-in-class approach to it, and dose escalation was completed within the project period. iOnctura's Series B was aimed mainly at another drug, and its plans for cambritaxestat in pancreatic cancer are not public.

What the project promised

Phase I/II development of an autotaxin inhibitor for pancreatic cancer, and investment on the back of it.

What the record shows

A completed 16-patient Phase Ib, orphan designation, an €80 million Series B, and no pancreatic Phase II found as of November 2026.

The Verdict

Early trial delivered, next step open

iOnctura ran the study the EIC funded and says it met its goal. The drug's future in pancreatic cancer depends on a Phase II that sources checked in November 2026 do not show.

iOnctura and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.

Industry

HealthBiopharmaceuticals

Focus
  • Undisclosed modality
Technologies
  • Medicinal chemistry
Keywords
  • Pancreatic cancer
  • Oncology
  • Autotaxin inhibitors
  • Fibrosis